Cardiovascular Risk and MASLD – Integrating Lipid Management with Novel Agents
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on X:
“Understanding MASLD, from molecular pathogenesis to cardiovascular risk.
A concise review for the clinical cardiologist.
MASLD not only drives liver injury but also worsens lipid metabolism, fueling atherogenic dyslipidemia. Increased VLDL, small dense LDL, dysfunctional HDL.
The review in ATH journal highlights that.
•Statins are both safe and effective in MASLD, yet underprescribed.
•Ezetimibe and pemafibrate may improve lipid profile and hepatic parameters.
•GLP-1RAs and SGLT2i show dual benefit on liver fat, cardiometabolic risk, and CVD outcomes.
•Emerging agents (resmetirom, lanifibranor) target both hepatic fibrosis and lipid metabolism.
Lipid-lowering therapy remains central in MASLD management, but must be integrated with newer agents for optimal cardio-hepatic protection .”
Read more here.
Stay informed with Hemostasis Today.
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
-
Aug 26, 2026, 13:59David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand
-
Aug 26, 2026, 13:54Giuseppe Biondi Zoccai: Congratulations to the Next Editor-in-Chief of the EHJ
-
Aug 26, 2026, 13:25Omar Adwan: Abnormal Nuclear Morphology of Neutrophil
-
Aug 26, 2026, 13:05Preventing Thrombosis with WTDay26
-
Aug 26, 2026, 10:09Gemma Figtree: How Well Do We Predict Heart Attack Risk in Women?
-
Aug 26, 2026, 10:06Understanding and Managing Fatigue in ITP – ITP Support Association
-
Aug 26, 2026, 10:04Abdul Muqtadir Abbasi: When a High INR Hides a Thrombotic Cancer
-
Aug 26, 2026, 09:42Mohammed Alo: What’s Wrong With the New Blood Pressure Guidelines?